Conference Coverage

Women and ACS: Focus on typical symptoms to improve outcomes


 

FROM GOING BACK TO THE HEART OF CARDIOLOGY

There are some differences in how women relative to men report symptoms of an acute coronary syndrome (ACS), but they should not be permitted to get in the way of prompt diagnosis and treatment, according to an expert review at the virtual Going Back to the Heart of Cardiology meeting.

Dr. Martha Gulati, Chief of Cardiology at the University of Arizona College of Medicine, Phoenix

Dr. Martha Gulati

“We need to get away from the idea that symptoms of a myocardial infarction in women are atypical, because women are also having typical symptoms,” said Martha Gulati, MD, chief of cardiology at the University of Arizona, Phoenix.

Sexes share key symptoms, but not treatment

Although “women are more likely to report additional symptoms,” chest pain “is pretty much equal between men and women” presenting with an ACS, according to Dr. Gulati.

There are several studies that have shown this, including the Variation in Recovery: Role of Gender on Outcomes of Young AMI patients (VIRGO). In VIRGO, which looked at ACS symptom presentation in younger patients (ages 18-55 years), 87.0% of women versus 89.5% of men presented with chest pain defined as pain, pressure, tightness, or discomfort.

Even among those who recognize that more women die of cardiovascular disease (CVD) disease than any other cause, nothing seems to erase the bias that women in an ED are less likely than men to be having a heart attack. About 60 million women in the United States have CVD, so no threat imposes a higher toll in morbidity and mortality.

In comparison, there are only about 3.5 million women with breast cancer. Even though this is a major cause of morbidity and mortality in women, it is dwarfed by CVD, according to statistics cited by Dr. Gulati. Yet, the data show women get inferior care by guideline-based standards.

“After a myocardial infarction, women relative to men are less likely to get aspirin or beta-blockers within 24 hours, they are less likely to undergo any type of invasive procedure, and they are less likely to meet the door-to-balloon time or receive any reperfusion therapy,” Dr. Gulati said. After a CVD event, “the only thing women do better is to die.”

Additional symptoms may muddy the diagnostic waters

In the setting of ACS, the problem is not that women fail to report symptoms that should lead clinicians to consider CVD, but that they report additional symptoms. For the clinician less inclined to consider CVD in women, particularly younger women, there is a greater risk of going down the wrong diagnostic pathway.

In other words, women report symptoms consistent with CVD, “but it is a question of whether we are hearing it,” Dr. Gulati said.

In the VIRGO study, 61.9% of women versus 54.8% of men (P < .001) presented three or more symptoms in addition to chest pain, such as epigastric symptoms, discomfort in the arms or neck, or palpitations. Women were more likely than men to attribute the symptoms to stress or anxiety (20.9% vs. 11.8%; P < .001), while less likely to consider them a result of muscle pain (15.4% vs. 21.2%; P = .029).

There are other gender differences for ACS. For example, women are more likely than men to presented ischemia without obstruction, but Dr. Gulati emphasized that lack of obstruction is not a reason to dismiss the potential for an underlying CV cause.

Pages

Recommended Reading

Combined OCT, cardiac MRI unravels root cause in most MINOCA
MDedge Cardiology
SCAPIS: Simple questionnaire can identify silent atherosclerosis
MDedge Cardiology
Cardiac arrest in COVID-19 pandemic: ‘Survival is possible’
MDedge Cardiology
Stenotic lesion outcomes better if fractional flow reserve guides PCI
MDedge Cardiology
Colchicine a case study for what’s wrong with U.S. drug pricing
MDedge Cardiology
Ticking all the right boxes for same-day discharge PCI
MDedge Cardiology
CVD deaths rose, imaging declined during pandemic
MDedge Cardiology
Tofacitinib for RA misses the mark in safety study
MDedge Cardiology
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
MDedge Cardiology
ColCORONA: More questions than answers for colchicine in COVID-19
MDedge Cardiology